董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Laura L. Forese Director 59 14.29万美元 未持股 2020-11-18
Ronnie Myers Independent Director 68 13.59万美元 未持股 2020-11-18
Karen N. Prange Independent Director 56 未披露 未持股 2020-11-18
Karen N. Prange Independent Director 56 14.60万美元 未持股 2020-11-18
Alan R. Batkin Lead Independent Director 76 16.44万美元 未持股 2020-11-18
Anthony B. Evnin Independent Director 79 12.85万美元 未持股 2020-11-18
George L. Fotiades Director, Chief Executive Officer 67 126.77万美元 未持股 2020-11-18
Charles M. Diker Director, Chairman of the Board 85 52.95万美元 未持股 2020-11-18
Mark N. Diker Director 54 12.50万美元 未持股 2020-11-18
Peter J. Pronovost Director 55 12.85万美元 未持股 2020-11-18
Ann E. Berman Independent Director 68 14.94万美元 未持股 2020-11-18

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Peter G. Clifford President and Chief Operating Officer 50 159.85万美元 未持股 2020-11-18
Shaun M. Blakeman Senior Vice President and Chief Financial Officer 42 76.82万美元 未持股 2020-11-18
Brian R. Capone Senior Vice President, Corporate Controller and Chief Accounting Officer 45 未披露 未持股 2020-11-18
Jean M. Casner Senior Vice President and Chief Human Resources Officer 62 未披露 未持股 2020-11-18
Jeff Z. Mann Senior Vice President, General Counsel and Secretary 48 88.83万美元 未持股 2020-11-18
George L. Fotiades Director, Chief Executive Officer 67 126.77万美元 未持股 2020-11-18
Seth M. Yellin Executive Vice President and Chief Growth Officer 46 85.66万美元 未持股 2020-11-18

董事简历

中英对照 |  中文 |  英文
Laura L. Forese

Laura L. Forese,NewYork-Presbyterian(一个全面的学术医疗输送系统,和两个著名医学院合作,Weill Cornell Medicine and Columbia University College of Physicians & Surgeons)副总裁和首席运营官。NewYork-Presbyterian包括学术医学中心、区域医院、雇佣和附属医生实践和动态和所有设施。Forese负责所有的企业运营以及并购和合伙企业战略执行。Forese从2013年到2015年担任NYP Healthcare System(如今已归入NewYork-Presbyterian)总裁;2011年到2015年担任Group SVP and COO NYP/Weill Cornell总裁。Forese自2003年起在NewYork-Presbyterian Hospital担任一系列管理职位。拥有矫形外科证书的她从1993年到2002年担任Columbia University实习教员;1998年到2002年担任副董事长。


Laura L. Forese, Executive Vice President and Chief Operating Officer of NewYork-Presbyterian, a comprehensive academic health care delivery system in collaboration with two renowned medical schools, Weill Cornell Medicine and Columbia University College of Physicians & Surgeons. NewYork-Presbyterian includes academic medical centers, regional hospitals, employed and affiliated physician practices and ambulatory and post-acute facilities. Dr. Forese is responsible for all enterprise operations, risk management, and strategy and execution of acquisitions and partnerships. She is also chairwoman of the board of directors of NIH Clinical Center, the nation’s premier hospital devoted to clinical research. Dr. Forese was President of NYP Healthcare System now subsumed into NewYork-Presbyterian from 2013 to 2015 and Group Senior Vice President and Chief Operating Officer of NYP/Weill Cornell from 2011 to 2015.
Laura L. Forese,NewYork-Presbyterian(一个全面的学术医疗输送系统,和两个著名医学院合作,Weill Cornell Medicine and Columbia University College of Physicians & Surgeons)副总裁和首席运营官。NewYork-Presbyterian包括学术医学中心、区域医院、雇佣和附属医生实践和动态和所有设施。Forese负责所有的企业运营以及并购和合伙企业战略执行。Forese从2013年到2015年担任NYP Healthcare System(如今已归入NewYork-Presbyterian)总裁;2011年到2015年担任Group SVP and COO NYP/Weill Cornell总裁。Forese自2003年起在NewYork-Presbyterian Hospital担任一系列管理职位。拥有矫形外科证书的她从1993年到2002年担任Columbia University实习教员;1998年到2002年担任副董事长。
Laura L. Forese, Executive Vice President and Chief Operating Officer of NewYork-Presbyterian, a comprehensive academic health care delivery system in collaboration with two renowned medical schools, Weill Cornell Medicine and Columbia University College of Physicians & Surgeons. NewYork-Presbyterian includes academic medical centers, regional hospitals, employed and affiliated physician practices and ambulatory and post-acute facilities. Dr. Forese is responsible for all enterprise operations, risk management, and strategy and execution of acquisitions and partnerships. She is also chairwoman of the board of directors of NIH Clinical Center, the nation’s premier hospital devoted to clinical research. Dr. Forese was President of NYP Healthcare System now subsumed into NewYork-Presbyterian from 2013 to 2015 and Group Senior Vice President and Chief Operating Officer of NYP/Weill Cornell from 2011 to 2015.
Ronnie Myers

Ronnie Myers,担任纽约医学院口腔医学托罗学院(Touro College of Dental Medicine at New York Medical College)的高级副院长,负责学术和行政事务(2016年6月以来)。他曾担任Columbia University College of Dental Medicine的行政副院长(2011年1月至2012年6月、2013年8月至2016年5月)。从2012年7月到2013年7月,他担任Columbia University College of Dental Medicine的临时院长。他曾担任牙科私人执业人员36年,目前发表牙科感染预防领域的讲座。


Ronnie Myers, Dean of the Touro College of Dental Medicine at New York Medical College since July 2017 previously having served as Senior Associate Dean for Academic and Administrative Affairs since June 2016. From January 2011 to June 2012 and then again from August 2013 to May 2016 Dr. Myers served as Vice Dean for Administration of Columbia University College of Dental Medicine. He served as Interim Dean of Columbia University College of Dental Medicine from July 2012 to July 2013 and Associate Dean for Clinical Affairs from 1997 to 2010. Dr. Myers maintained a private practice in general dentistry for 36 years and currently delivers lectures on the topic of infection prevention in the field of dentistry.
Ronnie Myers,担任纽约医学院口腔医学托罗学院(Touro College of Dental Medicine at New York Medical College)的高级副院长,负责学术和行政事务(2016年6月以来)。他曾担任Columbia University College of Dental Medicine的行政副院长(2011年1月至2012年6月、2013年8月至2016年5月)。从2012年7月到2013年7月,他担任Columbia University College of Dental Medicine的临时院长。他曾担任牙科私人执业人员36年,目前发表牙科感染预防领域的讲座。
Ronnie Myers, Dean of the Touro College of Dental Medicine at New York Medical College since July 2017 previously having served as Senior Associate Dean for Academic and Administrative Affairs since June 2016. From January 2011 to June 2012 and then again from August 2013 to May 2016 Dr. Myers served as Vice Dean for Administration of Columbia University College of Dental Medicine. He served as Interim Dean of Columbia University College of Dental Medicine from July 2012 to July 2013 and Associate Dean for Clinical Affairs from 1997 to 2010. Dr. Myers maintained a private practice in general dentistry for 36 years and currently delivers lectures on the topic of infection prevention in the field of dentistry.
Karen N. Prange
暂无中文简介

Karen N. Prange, Director of Nevro Corp. and AtriCure, Inc. since 2019. Previously Executive Vice President and Chief Executive Officer of Global Animal Health, Medical and Dental Surgical Group at Henry Schein Inc. Prior to that, she has held senior executive positions with leading medical device companies, including Boston Scientific Corporation, as Senior Vice President and President of the Urology and Pelvic Health business unit from 2012 to 2016 and Johnson & Johnson, where she spent 17 years in several cardiovascular, neurovascular and neuroscience medical device businesses. She also serves on the strategic advisory board of Nuvo Group, an emerging leader in maternal-fetal connected health.
暂无中文简介
Karen N. Prange, Director of Nevro Corp. and AtriCure, Inc. since 2019. Previously Executive Vice President and Chief Executive Officer of Global Animal Health, Medical and Dental Surgical Group at Henry Schein Inc. Prior to that, she has held senior executive positions with leading medical device companies, including Boston Scientific Corporation, as Senior Vice President and President of the Urology and Pelvic Health business unit from 2012 to 2016 and Johnson & Johnson, where she spent 17 years in several cardiovascular, neurovascular and neuroscience medical device businesses. She also serves on the strategic advisory board of Nuvo Group, an emerging leader in maternal-fetal connected health.
Karen N. Prange

Karen N. Prange最近于2016年至2018年担任Henry Schein, Inc.(以下简称“Henry Schein”)全球动物健康、医疗和牙科集团执行副总裁副总裁兼首席执行官以及执行委员会成员。在这个职位上,她领导的公司在三个不同的业务部门创造了超过60亿美元的收入,将业务发展到所有业务部门都高于市场的水平。在加入Henry Schein之前,她是波士顿科学公司的高级副总裁兼泌尿外科和盆腔健康业务总裁,并曾在强生公司担任微血管内血管和Codman神经血管业务总经理。除了担任一般管理职务外,Prange女士在商业和业务方面也有丰富的经验,包括管理创新管道以及收购和整合公司。Prange女士目前在WS Audiology A/S董事会任职,还曾于2019年9月起担任医疗器械公司Nuvo Group战略顾问,于2020年3月起担任全球投资机构EQT集团产业顾问。Prange女士以优异成绩在佛罗里达大学获得工商管理理学学士学位,并在加州大学洛杉矶分校安德森商学院和史密斯学院完成了高管教育课程。


Karen N. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein, Inc. ("Henry Schein") and a member of its Executive Committee from 2016 to 2018. In this role, she led a biness that generated over $6 billion of revenue across three different biness units, growing the biness to above market levels in all biness segments. Prior to her role at Henry Schein, she was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health biness and served as General Manager of the Micr Endovascular and Codman Neurovascular biness at Johnson & Johnson Company. In addition to general management roles, Ms. Prange has extensive experience in commercial and operational roles, including managing innovation pipelines and acquiring and integrating companies. Ms. Prange currently serves on the board of AtriCure, Inc. (NASDAQ: ATRC) and WS Audiology A/S. She has also served as Indtrial Advisor to EQT Group, a global investment organization, since March 2020.
Karen N. Prange最近于2016年至2018年担任Henry Schein, Inc.(以下简称“Henry Schein”)全球动物健康、医疗和牙科集团执行副总裁副总裁兼首席执行官以及执行委员会成员。在这个职位上,她领导的公司在三个不同的业务部门创造了超过60亿美元的收入,将业务发展到所有业务部门都高于市场的水平。在加入Henry Schein之前,她是波士顿科学公司的高级副总裁兼泌尿外科和盆腔健康业务总裁,并曾在强生公司担任微血管内血管和Codman神经血管业务总经理。除了担任一般管理职务外,Prange女士在商业和业务方面也有丰富的经验,包括管理创新管道以及收购和整合公司。Prange女士目前在WS Audiology A/S董事会任职,还曾于2019年9月起担任医疗器械公司Nuvo Group战略顾问,于2020年3月起担任全球投资机构EQT集团产业顾问。Prange女士以优异成绩在佛罗里达大学获得工商管理理学学士学位,并在加州大学洛杉矶分校安德森商学院和史密斯学院完成了高管教育课程。
Karen N. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein, Inc. ("Henry Schein") and a member of its Executive Committee from 2016 to 2018. In this role, she led a biness that generated over $6 billion of revenue across three different biness units, growing the biness to above market levels in all biness segments. Prior to her role at Henry Schein, she was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health biness and served as General Manager of the Micr Endovascular and Codman Neurovascular biness at Johnson & Johnson Company. In addition to general management roles, Ms. Prange has extensive experience in commercial and operational roles, including managing innovation pipelines and acquiring and integrating companies. Ms. Prange currently serves on the board of AtriCure, Inc. (NASDAQ: ATRC) and WS Audiology A/S. She has also served as Indtrial Advisor to EQT Group, a global investment organization, since March 2020.
Alan R. Batkin

Alan R. Batkin,战略咨询公司Converse联合公司的董事长兼CEO。2007年2月至2012年12月,他在投资公司美国对冲基金伊顿帕担任副董事长。在五年前,他是Kissinger联合公司的副董事长,这是家地理政治咨询公司,为多国企业提供咨询。他是纳斯达克上市的玩具游戏企业孩子宝的董事;纽交所上市公司Omnicom集团董事,是一家全球性的营销和公司沟通企业;纳斯达克上市Pattern能源集团董事,一家优质的独立电力公司。1999年至2012年6月,他在纽交所上市公司海外船舶控股集团担任董事。


Alan R. Batkin, Prior to his retirement in 2018 Mr. Batkin served as Chairman and Chief Executive Officer of Converse Associates, Inc., a strategic advisory firm, since January 2013 and continues to serve as a consultant for the firm. From February 2007 until December 2012 Mr. Batkin served as Vice Chairman of Eton Park Capital Management, L.P., an investment firm. For more than five years prior thereto, Mr. Batkin served as Vice Chairman of Kissinger Associates, Inc., a geopolitical consulting firm that advises multi-national companies. He is also a director of Mack-Cali Realty Corporation NYSE, a real estate investment trust, and was previously a director of Omnicom Group, Inc. (NYSE), a global marketing and corporate communications company, and Pattern Energy Group, Inc. (Nasdaq), an independent power company.
Alan R. Batkin,战略咨询公司Converse联合公司的董事长兼CEO。2007年2月至2012年12月,他在投资公司美国对冲基金伊顿帕担任副董事长。在五年前,他是Kissinger联合公司的副董事长,这是家地理政治咨询公司,为多国企业提供咨询。他是纳斯达克上市的玩具游戏企业孩子宝的董事;纽交所上市公司Omnicom集团董事,是一家全球性的营销和公司沟通企业;纳斯达克上市Pattern能源集团董事,一家优质的独立电力公司。1999年至2012年6月,他在纽交所上市公司海外船舶控股集团担任董事。
Alan R. Batkin, Prior to his retirement in 2018 Mr. Batkin served as Chairman and Chief Executive Officer of Converse Associates, Inc., a strategic advisory firm, since January 2013 and continues to serve as a consultant for the firm. From February 2007 until December 2012 Mr. Batkin served as Vice Chairman of Eton Park Capital Management, L.P., an investment firm. For more than five years prior thereto, Mr. Batkin served as Vice Chairman of Kissinger Associates, Inc., a geopolitical consulting firm that advises multi-national companies. He is also a director of Mack-Cali Realty Corporation NYSE, a real estate investment trust, and was previously a director of Omnicom Group, Inc. (NYSE), a global marketing and corporate communications company, and Pattern Energy Group, Inc. (Nasdaq), an independent power company.
Anthony B. Evnin

2006年9月以来,Anthony B. Evnin担任我们的董事会成员。从2001年6月起,他担任Infinity Discovery的董事会成员,直到2006年9月与我们的前身公司合并。自1975年以来,他担任Venrock公司的合伙人,一家风险投资公司。他担任AVEO Pharmaceuticals的董事,一家上市生物制药公司。他也担任Constellation Pharmaceuticals and Juno Therapeutics的董事,这2家公司都是私营生物制药公司。他担任洛克菲勒大学的受托人,杰克逊实验室的受托人,普林斯顿大学的名誉董事,董事监督会成员和纪念斯隆-凯特琳癌症中心的管理者,纽约基因组中心的主任,艾伯特和玛丽。拉斯科尔基金的董事会成员。之前,在过去的5年的时间里,他担任以下上市生物制药公司的董事包括:Acceleron Pharma,CymaBay Therapeutics,Memory Pharmaceuticals Corp.,Sunesis, Icagen,and Pharmos Corporation。并且在此之前,过去的5年的时间里,他担任以下私人控股公司的董事,包括:Acceleron Pharma,Altea Therapeutics Corporation,,and Celladon Corporation;(这些公司都是生物制药公司)and Boston-Power,一家锂蓄电池生产公司。他拥有普林斯顿大学的化学A.B。和麻省理工学院的化学博士学位。


Anthony B. Evnin, Partner of Venrock, a venture capital firm focused on technology and health care sectors, since 1975. Mr. Evnin currently serves on the board of directors of AVEO Pharmaceuticals, Inc. Nasdaq and Infinity Pharmaceuticals, Inc. (Nasdaq), as well as on the Boards of two private companies. He was formerly a director of over 35 companies, both public and private, in the life sciences area, including Constellation Pharmaceuticals, Inc. (Nasdaq) and Juno Therapeutics, Inc. (nasdaq). He is a Member of the Boards of Overseers and Managers of Memorial Sloan Kettering Cancer Center, a Trustee of The Jackson Laboratory, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, a Trustee Emeritus of Princeton University, and a Trustee Emeritus of The Rockefeller University. He holds a Ph.D. in Chemistry from the Massachusetts Institute of Technology.
2006年9月以来,Anthony B. Evnin担任我们的董事会成员。从2001年6月起,他担任Infinity Discovery的董事会成员,直到2006年9月与我们的前身公司合并。自1975年以来,他担任Venrock公司的合伙人,一家风险投资公司。他担任AVEO Pharmaceuticals的董事,一家上市生物制药公司。他也担任Constellation Pharmaceuticals and Juno Therapeutics的董事,这2家公司都是私营生物制药公司。他担任洛克菲勒大学的受托人,杰克逊实验室的受托人,普林斯顿大学的名誉董事,董事监督会成员和纪念斯隆-凯特琳癌症中心的管理者,纽约基因组中心的主任,艾伯特和玛丽。拉斯科尔基金的董事会成员。之前,在过去的5年的时间里,他担任以下上市生物制药公司的董事包括:Acceleron Pharma,CymaBay Therapeutics,Memory Pharmaceuticals Corp.,Sunesis, Icagen,and Pharmos Corporation。并且在此之前,过去的5年的时间里,他担任以下私人控股公司的董事,包括:Acceleron Pharma,Altea Therapeutics Corporation,,and Celladon Corporation;(这些公司都是生物制药公司)and Boston-Power,一家锂蓄电池生产公司。他拥有普林斯顿大学的化学A.B。和麻省理工学院的化学博士学位。
Anthony B. Evnin, Partner of Venrock, a venture capital firm focused on technology and health care sectors, since 1975. Mr. Evnin currently serves on the board of directors of AVEO Pharmaceuticals, Inc. Nasdaq and Infinity Pharmaceuticals, Inc. (Nasdaq), as well as on the Boards of two private companies. He was formerly a director of over 35 companies, both public and private, in the life sciences area, including Constellation Pharmaceuticals, Inc. (Nasdaq) and Juno Therapeutics, Inc. (nasdaq). He is a Member of the Boards of Overseers and Managers of Memorial Sloan Kettering Cancer Center, a Trustee of The Jackson Laboratory, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, a Trustee Emeritus of Princeton University, and a Trustee Emeritus of The Rockefeller University. He holds a Ph.D. in Chemistry from the Massachusetts Institute of Technology.
George L. Fotiades

George L. Fotiades,自2007年4月,他在Diamond Castle Holdings这一私营企业公司担任运营合伙人和董事长,负责医疗保健投资方面的事务,并任职了5年。此前,他曾在Cardinal Health公司担任总裁和首席运营官。该公司致力于提供医疗产品和服务,在同行内处于领先位置。此前,他曾在Cardinal公司的制药技术和服务部门担任总裁和首席执行官。该部门之后被Blackstone公司收购,后来更名为Catalent Pharma Solutions。自2007年至2010年,他曾是Catalent公司的董事长。目前,他在Prologis公司和AptarGroup公司担任董事。Prologis公司在纽约证券交易所上市,致力于持有、经营和开发产业房地产,在同行中处于领先地位。AptarGroup公司也在纽约证券交易所上市,是全球配送系统行业的翘楚。自2009年3月,他曾在Cantel公司担任副董事长,并担任非执行董事长。


George L. Fotiades,served as president and chief executive officer of Cantel Medical Corp., a provider of infection prevention and control products, from 2019 until his retirement in 2021. He was an operating partner at Five Arrows Capital Partners (Rothschild Merchant Banking) from April 2017 until March 2019. From April 2007 to April 2017, Mr. Fotiades was a partner, healthcare investments, at Diamond Castle Holdings LLP, a private equity firm. He was chairman of Catalent Pharma Solutions, Inc., a provider of advanced technologies for pharmaceutical, biotechnology and consumer health companies, from June 2007 to February 2010. Mr. Fotiades is a member of the board of AptarGroup, Inc., a global dispensing systems company. He previously served on the boards of Cantel Medical Corp. and Alberto-Culver Company, a consumer products company specializing in hair and skincare products.
George L. Fotiades,自2007年4月,他在Diamond Castle Holdings这一私营企业公司担任运营合伙人和董事长,负责医疗保健投资方面的事务,并任职了5年。此前,他曾在Cardinal Health公司担任总裁和首席运营官。该公司致力于提供医疗产品和服务,在同行内处于领先位置。此前,他曾在Cardinal公司的制药技术和服务部门担任总裁和首席执行官。该部门之后被Blackstone公司收购,后来更名为Catalent Pharma Solutions。自2007年至2010年,他曾是Catalent公司的董事长。目前,他在Prologis公司和AptarGroup公司担任董事。Prologis公司在纽约证券交易所上市,致力于持有、经营和开发产业房地产,在同行中处于领先地位。AptarGroup公司也在纽约证券交易所上市,是全球配送系统行业的翘楚。自2009年3月,他曾在Cantel公司担任副董事长,并担任非执行董事长。
George L. Fotiades,served as president and chief executive officer of Cantel Medical Corp., a provider of infection prevention and control products, from 2019 until his retirement in 2021. He was an operating partner at Five Arrows Capital Partners (Rothschild Merchant Banking) from April 2017 until March 2019. From April 2007 to April 2017, Mr. Fotiades was a partner, healthcare investments, at Diamond Castle Holdings LLP, a private equity firm. He was chairman of Catalent Pharma Solutions, Inc., a provider of advanced technologies for pharmaceutical, biotechnology and consumer health companies, from June 2007 to February 2010. Mr. Fotiades is a member of the board of AptarGroup, Inc., a global dispensing systems company. He previously served on the boards of Cantel Medical Corp. and Alberto-Culver Company, a consumer products company specializing in hair and skincare products.
Charles M. Diker

Charles M. Diker,Diker Management LLC董事长,注册投资顾问。Diker先生于1985年起担任Cantel Medical Corp.的董事并于1986年起担任董事会主席,直至2021年。


Charles M. Diker,Chairman of Diker Management LLC, a registered investment adviser. Mr. Diker was a director, from 1985, and Chairman of the Board, from 1986, of Cantel Medical Corp. until 2021.
Charles M. Diker,Diker Management LLC董事长,注册投资顾问。Diker先生于1985年起担任Cantel Medical Corp.的董事并于1986年起担任董事会主席,直至2021年。
Charles M. Diker,Chairman of Diker Management LLC, a registered investment adviser. Mr. Diker was a director, from 1985, and Chairman of the Board, from 1986, of Cantel Medical Corp. until 2021.
Mark N. Diker

Mark N. Diker在过去五年多时间里,是Diker Management LLC(注册投资顾问公司)创始人兼首席执行官。


Mark N. Diker, Chief Executive Officer and co-founder of Diker Management LLC, a registered investment adviser investing in innovative small cap growth companies across technology, consumer, industrial and healthcare industries. Mr. Diker was also a co-founding partner of Arsenal Capital Partners, a middle-market private equity firm making control investments in healthcare and industrial companies. Prior, Mr. Diker was a general partner at Geocapital Partners, a venture capital firm where he focused on investing in software, e-commerce, and business service growth stage companies, and held board positions of several private companies and one public company. Mr. Diker also worked for Bankers Trust Company in project finance and equity derivatives as a Vice President, stationed in Japan.
Mark N. Diker在过去五年多时间里,是Diker Management LLC(注册投资顾问公司)创始人兼首席执行官。
Mark N. Diker, Chief Executive Officer and co-founder of Diker Management LLC, a registered investment adviser investing in innovative small cap growth companies across technology, consumer, industrial and healthcare industries. Mr. Diker was also a co-founding partner of Arsenal Capital Partners, a middle-market private equity firm making control investments in healthcare and industrial companies. Prior, Mr. Diker was a general partner at Geocapital Partners, a venture capital firm where he focused on investing in software, e-commerce, and business service growth stage companies, and held board positions of several private companies and one public company. Mr. Diker also worked for Bankers Trust Company in project finance and equity derivatives as a Vice President, stationed in Japan.
Peter J. Pronovost

Peter J. Pronovost,在过去的五年多时间里,教授约翰霍普金斯大学医学院的麻醉学和重症监护医学部门的医学博士和教授;彭博公共卫生学院的卫生政策和管理系以及护理学院的了。此外,他还是练习麻醉师、重症监护医师、研究员、讲师和国际患者安全领袖。他也是病人安全和质量Armstrong Institute的主任;Medicine-National科学院研究所的一员,和Johns Hopkins Medicine's患者安全和质量控制中心的高级副总裁。他也是病人安全、ICU护理、卫生保健质量,循证医学,测量和评价的安全工作的讲师和作家。他的研究集中在重症监护室、操作套件、改善患者安全和其他临床领域提高卫生保健服务的质量。


Peter J. Pronovost, Chief Clinical Transformation Officer, University Hospitals since October 2018. Prior to that, beginning in January 2018 Dr. Pronovost served UnitedHealth Group Incorporated as its Senior Vice President for Clinical Strategy and then as its Chief Medical Officer. Previously, Dr. Pronovost was professor of anesthesiology and critical care medicine, surgery, nursing, health policy and management, engineering, and business at the Johns Hopkins University School of Medicine, where he had served since July 2011. He is a practicing critical care physician who is dedicated to finding ways to make hospitals and healthcare safer for patients. In June 2011 he was named director of the new Armstrong Institute for Patient Safety and Quality at Johns Hopkins, as well as Johns Hopkins Medicine’s senior vice president for patient safety and quality. Dr. Pronovost is also a member of the Institute of Medicine-National Academy of Science. In 2008 he was named one of Time magazine’s 100 most influential people in the world for his work in improving healthcare safety. He is a lecturer and author in the fields of patient safety and healthcare management. Additionally, Dr. Pronovost is a researcher centered on improving the quality of care. Previously, from January 2010 to June 2015 Dr. Pronovost served as a director of the Company.
Peter J. Pronovost,在过去的五年多时间里,教授约翰霍普金斯大学医学院的麻醉学和重症监护医学部门的医学博士和教授;彭博公共卫生学院的卫生政策和管理系以及护理学院的了。此外,他还是练习麻醉师、重症监护医师、研究员、讲师和国际患者安全领袖。他也是病人安全和质量Armstrong Institute的主任;Medicine-National科学院研究所的一员,和Johns Hopkins Medicine's患者安全和质量控制中心的高级副总裁。他也是病人安全、ICU护理、卫生保健质量,循证医学,测量和评价的安全工作的讲师和作家。他的研究集中在重症监护室、操作套件、改善患者安全和其他临床领域提高卫生保健服务的质量。
Peter J. Pronovost, Chief Clinical Transformation Officer, University Hospitals since October 2018. Prior to that, beginning in January 2018 Dr. Pronovost served UnitedHealth Group Incorporated as its Senior Vice President for Clinical Strategy and then as its Chief Medical Officer. Previously, Dr. Pronovost was professor of anesthesiology and critical care medicine, surgery, nursing, health policy and management, engineering, and business at the Johns Hopkins University School of Medicine, where he had served since July 2011. He is a practicing critical care physician who is dedicated to finding ways to make hospitals and healthcare safer for patients. In June 2011 he was named director of the new Armstrong Institute for Patient Safety and Quality at Johns Hopkins, as well as Johns Hopkins Medicine’s senior vice president for patient safety and quality. Dr. Pronovost is also a member of the Institute of Medicine-National Academy of Science. In 2008 he was named one of Time magazine’s 100 most influential people in the world for his work in improving healthcare safety. He is a lecturer and author in the fields of patient safety and healthcare management. Additionally, Dr. Pronovost is a researcher centered on improving the quality of care. Previously, from January 2010 to June 2015 Dr. Pronovost served as a director of the Company.
Ann E. Berman

Ann E. Berman从2006年1月开始担任公司的董事。她担任审计委员会的主席,并担任公司董事会下属的薪酬与提名和治理委员会的委员。从2006年4月到2009年6月,Berman女士担任哈佛大学高级顾问,并从2002年10月到2006年4月担任哈佛大学财务部副总裁兼首席财务官。Berman女士还从2006年开始担任美国洛斯保险公司(Loews Corporation)的董事,并从2011年3月开始担任卡特尔医疗公司(Cantel Medical Corp.)的董事。


Ann E. Berman,Retired advisor to the President of Harvard University. Ms. Berman is also the Chair of the Board of Immuneering Corporation. Ms. Berman was a director of Renalytix plc from 2021 until 2022, Cantel Medical Corp. from 2011 until 2021 and Eaton Vance Corporation from 2006 until 2021.
Ann E. Berman从2006年1月开始担任公司的董事。她担任审计委员会的主席,并担任公司董事会下属的薪酬与提名和治理委员会的委员。从2006年4月到2009年6月,Berman女士担任哈佛大学高级顾问,并从2002年10月到2006年4月担任哈佛大学财务部副总裁兼首席财务官。Berman女士还从2006年开始担任美国洛斯保险公司(Loews Corporation)的董事,并从2011年3月开始担任卡特尔医疗公司(Cantel Medical Corp.)的董事。
Ann E. Berman,Retired advisor to the President of Harvard University. Ms. Berman is also the Chair of the Board of Immuneering Corporation. Ms. Berman was a director of Renalytix plc from 2021 until 2022, Cantel Medical Corp. from 2011 until 2021 and Eaton Vance Corporation from 2006 until 2021.

高管简历

中英对照 |  中文 |  英文
Peter G. Clifford

Peter G. Clifford,自2015年3月起担任公司执行副总裁和首席财务官。加入公司之前,Clifford曾在20年间担任多个金融职位。他自2009年4月起担任IDEX Corporation运营金融和信息技术集团副总裁。


Peter G. Clifford has served as the President and Chief Operating Officer of the Company since August 2020 and as Executive Vice President and Chief Operating Officer since May 2019. Prior to his appointment as Chief Operating Officer, Mr. Clifford served as Executive Vice President and Chief Financial Officer of the Company since May 2015. Prior to joining the Company, Mr. Clifford served in various financial positions with increasing responsibility for over twenty years. For more than five years prior to joining the Company, he was Group Vice President of Operations Finance and Information Technology for IDEX Corporation.
Peter G. Clifford,自2015年3月起担任公司执行副总裁和首席财务官。加入公司之前,Clifford曾在20年间担任多个金融职位。他自2009年4月起担任IDEX Corporation运营金融和信息技术集团副总裁。
Peter G. Clifford has served as the President and Chief Operating Officer of the Company since August 2020 and as Executive Vice President and Chief Operating Officer since May 2019. Prior to his appointment as Chief Operating Officer, Mr. Clifford served as Executive Vice President and Chief Financial Officer of the Company since May 2015. Prior to joining the Company, Mr. Clifford served in various financial positions with increasing responsibility for over twenty years. For more than five years prior to joining the Company, he was Group Vice President of Operations Finance and Information Technology for IDEX Corporation.
Shaun M. Blakeman

ShaunM.Blakeman自2019年5月起担任公司高级副总裁兼首席财务官。在这个角色上,他负责所有的财务报告、财务规划和分析、审计、财政、战略规划和管理以及投资者关系。Blakeman先生于2016年至2018年在Cantel工作,担任Cantel&8217;s Medical Division的财务Vice President。在重新加入公司之前,Blakeman先生是Medtronic plc的高级财务总监。在此之前,他在IDEX Corporation担任领导职务,并承担越来越多的责任,包括Vice President、隔膜和加药泵平台业务,以及IDEX的另一个部门Warren Rupp,Inc.拉丁美洲业务的财务总监。


Shaun M. Blakeman has served as Senior Vice President and Chief Financial Officer of the Company since May 2019. In this role, he is responsible for all financial reporting, financial planning and analysis, auditing, treasury, strategic planning and management, and investor relations. Mr. Blakeman worked for Cantel from 2016 to 2018 serving as the Vice President of Finance for Cantel’s Medical division. Prior to rejoining the Company, Mr. Blakeman was Senior Finance Director at Medtronic plc. Prior to that, he held leadership roles with increasing responsibility including Vice President, Diaphragm and Dosing Pump Platform business at IDEX Corporation and Controller for Latin American Operations for Warren Rupp, Inc., another division of IDEX.
ShaunM.Blakeman自2019年5月起担任公司高级副总裁兼首席财务官。在这个角色上,他负责所有的财务报告、财务规划和分析、审计、财政、战略规划和管理以及投资者关系。Blakeman先生于2016年至2018年在Cantel工作,担任Cantel&8217;s Medical Division的财务Vice President。在重新加入公司之前,Blakeman先生是Medtronic plc的高级财务总监。在此之前,他在IDEX Corporation担任领导职务,并承担越来越多的责任,包括Vice President、隔膜和加药泵平台业务,以及IDEX的另一个部门Warren Rupp,Inc.拉丁美洲业务的财务总监。
Shaun M. Blakeman has served as Senior Vice President and Chief Financial Officer of the Company since May 2019. In this role, he is responsible for all financial reporting, financial planning and analysis, auditing, treasury, strategic planning and management, and investor relations. Mr. Blakeman worked for Cantel from 2016 to 2018 serving as the Vice President of Finance for Cantel’s Medical division. Prior to rejoining the Company, Mr. Blakeman was Senior Finance Director at Medtronic plc. Prior to that, he held leadership roles with increasing responsibility including Vice President, Diaphragm and Dosing Pump Platform business at IDEX Corporation and Controller for Latin American Operations for Warren Rupp, Inc., another division of IDEX.
Brian R. Capone

BrianR.Capone于2018年10月被任命为高级副总裁,公司财务总监兼首席会计官,此前曾于2017年4月起担任公司Vice President,首席会计官和Vice President兼公司财务总监。在加入公司之前,卡彭先生于2014年10月至2017年4月担任史赛克公司助理公司财务总监,并于2012年3月至2014年10月担任奎斯特诊疗公司外部财务报告和技术会计总监。在担任这些职务之前,卡彭先生曾在健赞公司和CVS Health Corporation公司担任过各种财务报告职务。


Brian R. Capone was appointed Senior Vice President, Corporate Controller and Chief Accounting Officer in October 2018 having previously served as Vice President, Chief Accounting Officer and Vice President, Corporate Controller for the Company since April 2017. Prior to joining the Company, Mr. Capone served as the Assistant Corporate Controller for Stryker Corporation from October 2014 to April 2017 and Director, External Financial Reporting and Technical Accounting for Quest Diagnostics Incorporated from March 2012 to October 2014. Prior to those roles, Mr. Capone served in various financial reporting roles at Genzyme Corporation and CVS Health Corporation.
BrianR.Capone于2018年10月被任命为高级副总裁,公司财务总监兼首席会计官,此前曾于2017年4月起担任公司Vice President,首席会计官和Vice President兼公司财务总监。在加入公司之前,卡彭先生于2014年10月至2017年4月担任史赛克公司助理公司财务总监,并于2012年3月至2014年10月担任奎斯特诊疗公司外部财务报告和技术会计总监。在担任这些职务之前,卡彭先生曾在健赞公司和CVS Health Corporation公司担任过各种财务报告职务。
Brian R. Capone was appointed Senior Vice President, Corporate Controller and Chief Accounting Officer in October 2018 having previously served as Vice President, Chief Accounting Officer and Vice President, Corporate Controller for the Company since April 2017. Prior to joining the Company, Mr. Capone served as the Assistant Corporate Controller for Stryker Corporation from October 2014 to April 2017 and Director, External Financial Reporting and Technical Accounting for Quest Diagnostics Incorporated from March 2012 to October 2014. Prior to those roles, Mr. Capone served in various financial reporting roles at Genzyme Corporation and CVS Health Corporation.
Jean M. Casner

JeanM.Casner自2019年3月起担任公司高级副总裁兼首席人力资源官。担任该职位时,她负责全球人力资源职能,包括其人才战略、政策、系统和流程,如人才管理、继任规划、学习和发展、薪酬和福利、绩效和招聘。Casner女士于2017年加入Cantel,担任Vice President,福利,薪酬和人力资源运营。在加入Cantel之前,Casner女士于2008年7月至2015年5月在美国国家篮球协会(National Basketball Association)担任人力资源领导职位,从2004年1月到2008年6月,Dial公司从1993年7月到2001年7月归汉高公司所有,从1991年到1993年归强生公司所有,从1980年9月到1990年12月归ORC Worldwide公司(现在归Mercer LLC所有)所有。


Jean M. Casner has served as the Company’s Senior Vice President and Chief Human Resources Officer since March 2019. In this role, she is responsible for the global human resources function, including its people strategy, policies, systems and processes such as talent management, succession planning, learning and development, compensation and benefits, performance and recruiting. Ms. Casner joined Cantel in 2017 as Vice President, Benefits, Compensation and HR Operations. Prior to Cantel, Ms. Casner held HR leadership positions at the National Basketball Association from July 2008 to May 2015 Merck & Co., Inc. from January 2004 to June 2008 The Dial Corporation now owned by Henkel Corporation from July 1993 to July 2001 Johnson & Johnson from 1991 to 1993 and ORC Worldwide (now owned by Mercer LLC) from September of 1980 to December 1990.
JeanM.Casner自2019年3月起担任公司高级副总裁兼首席人力资源官。担任该职位时,她负责全球人力资源职能,包括其人才战略、政策、系统和流程,如人才管理、继任规划、学习和发展、薪酬和福利、绩效和招聘。Casner女士于2017年加入Cantel,担任Vice President,福利,薪酬和人力资源运营。在加入Cantel之前,Casner女士于2008年7月至2015年5月在美国国家篮球协会(National Basketball Association)担任人力资源领导职位,从2004年1月到2008年6月,Dial公司从1993年7月到2001年7月归汉高公司所有,从1991年到1993年归强生公司所有,从1980年9月到1990年12月归ORC Worldwide公司(现在归Mercer LLC所有)所有。
Jean M. Casner has served as the Company’s Senior Vice President and Chief Human Resources Officer since March 2019. In this role, she is responsible for the global human resources function, including its people strategy, policies, systems and processes such as talent management, succession planning, learning and development, compensation and benefits, performance and recruiting. Ms. Casner joined Cantel in 2017 as Vice President, Benefits, Compensation and HR Operations. Prior to Cantel, Ms. Casner held HR leadership positions at the National Basketball Association from July 2008 to May 2015 Merck & Co., Inc. from January 2004 to June 2008 The Dial Corporation now owned by Henkel Corporation from July 1993 to July 2001 Johnson & Johnson from 1991 to 1993 and ORC Worldwide (now owned by Mercer LLC) from September of 1980 to December 1990.
Jeff Z. Mann

JeffZ.Mann于2019年8月1日被任命为高级副总裁,总法律顾问兼公司秘书,并自2020年3月起担任公司首席合规官。在2020财年,Mann先生还担任全球研发临时负责人。在此之前,Mann先生自2018年6月起担任公司Vice President兼副总法律顾问。Mann先生自2004年起在波士顿科学国际有限公司担任多个法律领导职位后加入该公司。


Jeff Z. Mann was appointed Senior Vice President, General Counsel and Secretary of the Company as of August 1 2019 and has additionally served as the Chief Compliance Officer for the Company since March 2020. During fiscal year 2020 Mr. Mann also served as the interim leader for Global R&D. Prior to that, Mr. Mann served as the Vice President, Deputy General Counsel of the Company since June 2018. Mr. Mann joined the Company after serving in various legal leadership roles at Boston Scientific Corporation since 2004.
JeffZ.Mann于2019年8月1日被任命为高级副总裁,总法律顾问兼公司秘书,并自2020年3月起担任公司首席合规官。在2020财年,Mann先生还担任全球研发临时负责人。在此之前,Mann先生自2018年6月起担任公司Vice President兼副总法律顾问。Mann先生自2004年起在波士顿科学国际有限公司担任多个法律领导职位后加入该公司。
Jeff Z. Mann was appointed Senior Vice President, General Counsel and Secretary of the Company as of August 1 2019 and has additionally served as the Chief Compliance Officer for the Company since March 2020. During fiscal year 2020 Mr. Mann also served as the interim leader for Global R&D. Prior to that, Mr. Mann served as the Vice President, Deputy General Counsel of the Company since June 2018. Mr. Mann joined the Company after serving in various legal leadership roles at Boston Scientific Corporation since 2004.
George L. Fotiades

George L. Fotiades,自2007年4月,他在Diamond Castle Holdings这一私营企业公司担任运营合伙人和董事长,负责医疗保健投资方面的事务,并任职了5年。此前,他曾在Cardinal Health公司担任总裁和首席运营官。该公司致力于提供医疗产品和服务,在同行内处于领先位置。此前,他曾在Cardinal公司的制药技术和服务部门担任总裁和首席执行官。该部门之后被Blackstone公司收购,后来更名为Catalent Pharma Solutions。自2007年至2010年,他曾是Catalent公司的董事长。目前,他在Prologis公司和AptarGroup公司担任董事。Prologis公司在纽约证券交易所上市,致力于持有、经营和开发产业房地产,在同行中处于领先地位。AptarGroup公司也在纽约证券交易所上市,是全球配送系统行业的翘楚。自2009年3月,他曾在Cantel公司担任副董事长,并担任非执行董事长。


George L. Fotiades,served as president and chief executive officer of Cantel Medical Corp., a provider of infection prevention and control products, from 2019 until his retirement in 2021. He was an operating partner at Five Arrows Capital Partners (Rothschild Merchant Banking) from April 2017 until March 2019. From April 2007 to April 2017, Mr. Fotiades was a partner, healthcare investments, at Diamond Castle Holdings LLP, a private equity firm. He was chairman of Catalent Pharma Solutions, Inc., a provider of advanced technologies for pharmaceutical, biotechnology and consumer health companies, from June 2007 to February 2010. Mr. Fotiades is a member of the board of AptarGroup, Inc., a global dispensing systems company. He previously served on the boards of Cantel Medical Corp. and Alberto-Culver Company, a consumer products company specializing in hair and skincare products.
George L. Fotiades,自2007年4月,他在Diamond Castle Holdings这一私营企业公司担任运营合伙人和董事长,负责医疗保健投资方面的事务,并任职了5年。此前,他曾在Cardinal Health公司担任总裁和首席运营官。该公司致力于提供医疗产品和服务,在同行内处于领先位置。此前,他曾在Cardinal公司的制药技术和服务部门担任总裁和首席执行官。该部门之后被Blackstone公司收购,后来更名为Catalent Pharma Solutions。自2007年至2010年,他曾是Catalent公司的董事长。目前,他在Prologis公司和AptarGroup公司担任董事。Prologis公司在纽约证券交易所上市,致力于持有、经营和开发产业房地产,在同行中处于领先地位。AptarGroup公司也在纽约证券交易所上市,是全球配送系统行业的翘楚。自2009年3月,他曾在Cantel公司担任副董事长,并担任非执行董事长。
George L. Fotiades,served as president and chief executive officer of Cantel Medical Corp., a provider of infection prevention and control products, from 2019 until his retirement in 2021. He was an operating partner at Five Arrows Capital Partners (Rothschild Merchant Banking) from April 2017 until March 2019. From April 2007 to April 2017, Mr. Fotiades was a partner, healthcare investments, at Diamond Castle Holdings LLP, a private equity firm. He was chairman of Catalent Pharma Solutions, Inc., a provider of advanced technologies for pharmaceutical, biotechnology and consumer health companies, from June 2007 to February 2010. Mr. Fotiades is a member of the board of AptarGroup, Inc., a global dispensing systems company. He previously served on the boards of Cantel Medical Corp. and Alberto-Culver Company, a consumer products company specializing in hair and skincare products.
Seth M. Yellin

2012年4月,Seth M. Yellin先生在Company工作,并担任企业发展高级副总裁。从2011年1月到2012年1月,他在Citadel Asset Management的医疗设备和生命科学部担任分析师,2009年5月到2011年1月,他在 Millennium Partners担任高级医疗保健分析师和常务董事。四年多前,他担任 Brencourt Advisors LLC的US Event-Driven Portfolio 的副主席。


Seth M. Yellin has served as Executive Vice President and Chief Growth Officer of the Company since February 2020 and prior to that as Executive Vice President, Strategy and Corporate Development since September 2016. Previously, from March 2013 to September 2016 he served as Senior Vice President, Corporate Development, and from April 2012 through March 2013 he served as Vice President, Corporate Development. From January 2011 through January 2012 Mr. Yellin was an analyst in the Medical Devices & Life Science Tools segment of Citadel Asset Management.
2012年4月,Seth M. Yellin先生在Company工作,并担任企业发展高级副总裁。从2011年1月到2012年1月,他在Citadel Asset Management的医疗设备和生命科学部担任分析师,2009年5月到2011年1月,他在 Millennium Partners担任高级医疗保健分析师和常务董事。四年多前,他担任 Brencourt Advisors LLC的US Event-Driven Portfolio 的副主席。
Seth M. Yellin has served as Executive Vice President and Chief Growth Officer of the Company since February 2020 and prior to that as Executive Vice President, Strategy and Corporate Development since September 2016. Previously, from March 2013 to September 2016 he served as Senior Vice President, Corporate Development, and from April 2012 through March 2013 he served as Vice President, Corporate Development. From January 2011 through January 2012 Mr. Yellin was an analyst in the Medical Devices & Life Science Tools segment of Citadel Asset Management.